LLY · ELI LILLY & Co

$1,223.35 +25.82 (+2.16%)

Market Cap

$1.13T

941.74M

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Revenue

$65.18B +44.7%

FY2025

Net Income

$20.64B +94.9%

FY2025

Gross Margin

83.04% +1.7pp

FY2025

Diluted EPS

$22.95 +96%

FY2025

Operating Cash Flow

$16.81B +90.7%

FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow Adjusted All Metrics

Annual Quarterly

Line Item	3Y	5Y	10Y	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009	FY2008	FY2007
Revenue	+31.7%	+21.6%	+12.6%	$72.25B	$65.18B	$45.04B	$34.12B	$28.54B	$28.32B	$24.54B	$22.32B	$21.49B	$19.97B	$18.31B	$19.96B	$19.62B	$23.11B	$22.6B	$24.29B	$23.08B	$21.84B	$20.37B	$18.63B
Cost of Revenue	+18.6%	+15.0%	+8.2%	$12.4B	$11.05B	$8.42B	$7.08B	$6.63B	$7.31B	$5.48B	$4.72B	$4.68B	$4.45B	$4.16B	$5.04B	$4.93B	$4.91B	$4.8B	$5.07B	$4.37B	$4.25B	$4.38B	$4.25B
Gross Profit	+35.2%	+23.2%	+13.8%	$59.85B	$54.13B	$36.63B	$27.04B	$21.91B	$21.01B	$19.06B	$17.6B	$16.81B	$15.53B	$14.15B	$14.92B	$14.68B	$18.21B	$17.81B	$19.22B	$18.71B	$17.59B	$16B	$14.38B
Gross Margin	—	—	—	—	83.04%	81.31%	79.25%	76.77%	74.18%	77.66%	78.85%	78.22%	77.73%	77.28%	74.76%	74.85%	78.76%	78.78%	79.13%	81.08%	80.55%	78.52%	77.2%
Research & Development	+22.9%	+17.4%	+10.8%	$14.11B	$13.34B	$10.99B	$9.31B	$7.19B	$6.93B	$5.98B	$5.6B	$5.05B	$5.1B	$5.04B	$4.8B	$4.73B	$5.53B	$5.28B	$5.02B	$4.88B	$4.33B	$3.84B	$3.49B
Selling, General & Administrative	+19.9%	+12.6%	+5.4%	$11.56B	$11.09B	$8.59B	$7.4B	$6.44B	$6.43B	$6.12B	$6.21B	$5.98B	$5.98B	$5.84B	$6.53B	$6.62B	$7.13B	$7.51B	$7.88B	$7.05B	$6.89B	$6.63B	$6.1B
Amortization of Intangibles	-5.6%	+2.6%	-2.5%	—	$488M	$553M	$506M	$579.7M	$628.8M	$428.2M	$225.8M	$361.3M	$462.2M	$517.2M	$631.8M	$535.9M	$555M	$563M	$469M	$385.7M	—	—	—
Depreciation & Amortization	+9.5%	+8.6%	+3.4%	—	$2B	$1.77B	$1.53B	$1.52B	$1.55B	$1.32B	$1.23B	$1.61B	$1.57B	$1.5B	$1.43B	$1.38B	$1.45B	$1.46B	$1.37B	$1.33B	$1.3B	$1.12B	-$1.05B
Interest Expense	+39.2%	+20.0%	+18.7%	—	$895M	$781M	$485.9M	$331.6M	$339.8M	$359.6M	$400.6M	$242.5M	$225M	$185.2M	$161.2M	$148.8M	$160.1M	$177.8M	$186M	$185.5M	$261.3M	-$228.3M	—
Interest Income	+90.4%	+16.9%	+3.8%	$197.6M	—	$175.2M	$173.6M	$62.8M	$25.4M	$33M	$80.4M	$159.3M	$166.4M	$107.9M	$87M	$121M	$119.7M	$105M	$79.9M	$51.9M	$75.2M	-$210.7M	—
Other Non-Operating Income	—	—	—	-$397M	-$571M	-$219M	$97M	-$320.9M	-$201.6M	$1.17B	$291.6M	$145.6M	$301.5M	$108.8M	$100.6M	$340.5M	$518.9M	$674M	-$179M	-$5M	-$229.5M	$26.1M	$122M
Investment Income (Loss)	—	—	—	—	—	-$49.8M	-$23.5M	-$420M	$178M	$1.44B	$403.1M	$27M	—	—	—	—	—	—	—	—	—	—	—
Pretax Income	+55.8%	+28.9%	+24.9%	$31.13B	$25.73B	$12.68B	$6.55B	$6.81B	$6.16B	$7.23B	$5.27B	$3.68B	$2.3B	$3.28B	$2.79B	$3B	$5.89B	$4.9B	$6.14B	$6.77B	$5.36B	-$1.31B	$3.88B
Income Tax	+108.5%	+37.5%	+29.6%	$5.85B	$5.09B	$2.09B	$1.31B	$561.6M	$573.8M	$1.04B	$628M	$529.5M	$2.39B	$551.4M	$381.6M	$609.8M	$1.2B	$1.32B	$1B	$1.46B	$1.03B	$764.3M	$923.8M
Net Income	+49.0%	+27.2%	+24.0%	$25.28B	$20.64B	$10.59B	$5.24B	$6.24B	$5.58B	$6.19B	$8.32B	$3.23B	-$204.1M	$2.74B	$2.41B	$2.39B	$4.68B	$4.09B	$4.35B	$5.07B	$4.33B	-$2.07B	$2.95B
Net Margin	—	—	—	—	31.67%	23.51%	15.36%	21.88%	19.71%	25.24%	37.27%	15.04%	-1.02%	14.95%	12.07%	12.19%	20.27%	18.09%	17.9%	21.97%	19.82%	-10.17%	15.85%
Net Income Available to Common Stockholders	-1.9%	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	$4.09B	$4.35B	$5.07B	$4.33B	-$2.07B	—
Comprehensive Income	+48.5%	+28.8%	+28.4%	$26.22B	$22.08B	$10.6B	$4.76B	$6.74B	$7.74B	$6.22B	—	—	—	$2.09B	$1.82B	$401.4M	$6.48B	$4.15B	$3.16B	$4.87B	$4.64B	-$4.87B	$4.35B
EPS (Basic) USD/shares	+49.2%	+27.5%	+26.1%	—	$23.00	$11.76	$5.82	$6.93	$6.15	$6.82	$8.93	$3.14	-$0.19	$2.59	$2.27	$2.23	$4.33	$3.67	$3.90	$4.58	$3.94	-$1.89	—
EPS (Diluted) USD/shares	+49.3%	+27.6%	+26.1%	—	$22.95	$11.71	$5.80	$6.90	$6.12	$6.79	$8.89	$3.13	-$0.19	$2.58	$2.26	$2.23	$4.32	$3.66	$3.90	$4.58	$3.94	-$1.89	—
Shares Outstanding (Basic Avg) shares	-0.2%	-0.2%	-1.7%	—	897.3M	900.6M	900.2M	901.74M	906.96M	907.63M	931.06M	1.03B	1.05B	1.06B	1.06B	1.07B	1.08B	1.11B	1.11B	1.11B	1.1B	1.09B	—
Shares Outstanding (Diluted Avg) shares	-0.2%	-0.3%	-1.7%	—	899.3M	904.1M	903.3M	904.62M	911.68M	912.51M	935.68M	1.03B	1.05B	1.06B	1.07B	1.07B	1.08B	1.12B	1.11B	1.11B	1.1B	1.09B	—

Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2007–FY2025: $24.03B in buybacks, $51.46B in dividends.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue

16.14×

Peer median 5.57×

EV/EBIT

—

P/E (TTM)

42.54×

Peer median 28.54×

Peer medians compare against the 8 similar-size Drug Manufacturers - General companies (of 14 listed).

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component	FY2025	FY2024	FY2023	FY2022
Reportable Segment	$65,179,000,000	$45,043,000,000	$34,124,000,000	$28,541,400,000

By Geography (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
United States	$43,481,000,000	$30,375,000,000	$21,791,000,000	$18,190,000,000	$16,811,000,000	$14,229,300,000	$12,722,600,000	$12,391,900,000
Non Us	$21,698,000,000	$14,668,000,000	$12,333,000,000	$10,351,300,000	$11,507,400,000	$10,310,500,000	$9,596,800,000	$9,101,400,000
Europe	$11,558,000,000	$6,921,000,000	$6,175,000,000	$4,299,200,000	$4,776,800,000	$4,187,700,000	$3,765,000,000	$3,663,100,000
Rest of World	$6,057,000,000	$4,271,000,000	$2,946,000,000	$2,852,000,000	—	—	—	—
Japan	$2,132,000,000	$1,815,000,000	$1,673,000,000	$1,747,300,000	$2,367,000,000	$2,583,100,000	$2,547,600,000	$2,407,400,000
China	$1,951,000,000	$1,660,000,000	$1,540,000,000	$1,452,800,000	$1,661,400,000	$1,116,900,000	$939,400,000	$750,800,000
Other Foreign Countries	—	—	$2,946,200,000	$2,852,000,000	$2,702,200,000	$2,422,700,000	$2,344,900,000	$2,280,100,000

By Product & Service (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Product	$60,958,000,000	$40,748,000,000	$28,814,000,000	$25,462,800,000	$25,957,900,000	$22,694,800,000	$20,377,300,000	$19,866,400,000
Collaboration and Other Revenue	$4,221,000,000	$4,295,000,000	$5,310,000,000	$3,078,600,000	$2,360,500,000	$1,845,000,000	$1,942,200,000	$1,626,900,000
Jardiance	$3,432,000,000	$3,341,000,000	$2,745,000,000	$2,066,000,000	$1,490,800,000	$1,153,800,000	$944,200,000	$658,300,000
Bamlanivimab	—	—	—	—	—	$871,200,000	—	—
Basaglar	—	$676,900,000	$728,300,000	$760,400,000	$892,500,000	$1,124,400,000	$1,112,600,000	$801,200,000
COVID19 Antibodies	—	$0	$0	$2,020,000,000	$2,240,000,000	$871,200,000	—	—
Olumiant	—	$957,400,000	$922,600,000	$830,500,000	$1,115,100,000	$638,900,000	$426,900,000	$202,500,000
Trajenta BI	—	—	$386,900,000	$383,700,000	$372,500,000	$358,500,000	$590,600,000	$574,700,000
TYVYT	—	$526,000,000	$393,400,000	$293,300,000	$418,100,000	$308,700,000	$134,000,000	—
Royalty	—	—	$191,600,000	$163,400,000	$175,000,000	$135,600,000	$301,500,000	$303,200,000

Key facts CIK 59478 CUSIP 532457108 13F (30d) 1751 filings 1705 filers Visit website Investor relations